Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.
J Clin Microbiol. 2018 Mar 26;56(4). doi: 10.1128/JCM.01972-17. Print 2018 Apr.
Since the emergence and dissemination of Zika virus (ZIKV) in late 2015, our understanding of the biology, transmission, clinical disease, and potential sequelae associated with infection has markedly expanded. Over the past 2 years, the number of diagnostic assays for ZIKV has increased from none in 2015 to 5 serological assays and 14 molecular assays in 2017, all with emergency use authorization granted through the U.S. Food and Drug Administration. Here we provide an update on ZIKV, addressing what we have collectively learned since the outbreak began, including a summary of currently available diagnostic assays for this virus.
自 Zika 病毒（ZIKV）于 2015 年末出现和传播以来，我们对其生物学、传播、临床疾病以及感染相关的潜在后遗症的认识显著扩展。在过去的两年中，ZIKV 的诊断检测数量从 2015 年的零项增加到 2017 年的 5 项血清学检测和 14 项分子检测，所有这些检测均通过美国食品和药物管理局获得了紧急使用授权。在这里，我们提供了关于 ZIKV 的最新信息，介绍了自疫情爆发以来我们共同学到的内容，包括对目前用于这种病毒的诊断检测方法的总结。
